Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services

Fineline Cube Jan 23, 2026
Company Deals

PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline

Fineline Cube Jan 23, 2026
Company Deals

Bio‑Sincerity Pharma‑Tech Secures Greater China Priority Rights for Delim’s Semaglutide and Tirzepatide Portfolio

Fineline Cube Jan 23, 2026
Company Deals

TaiGen and Joincare Partner on TG‑4318 DPP1 Inhibitor for Bronchiectasis in Greater China

Fineline Cube Jan 23, 2026
Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Fineline Cube Jan 22, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials

Fineline Cube Jan 23, 2026
Company Drug

AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis

Fineline Cube Jan 23, 2026
Company Drug

CARsgen Completes Patient Enrollment for Phase II Trial of CT041 in Advanced Gastric Cancer

Fineline Cube Aug 19, 2024

CARsgen Therapeutics Holdings Ltd (HKG: 2171), a leading China-based developer of chimeric antigen receptor (CAR)-T...

Company Deals

Bio-Thera Solutions Expands Reach with New Licensing Deal for Biosimilar BAT2306

Fineline Cube Aug 19, 2024

Guangzhou-based Bio-Thera Solutions (SHA: 688177) has entered into a new licensing agreement with Russian firm...

Company

Evotec to Cut 400 Jobs Amid R&D Slowdown and Corporate Restructuring

Fineline Cube Aug 16, 2024

Evotec SE (NASDAQ: EVO), a Germany-based Contract Research and Development Organization (CRO/CDMO), has announced plans...

Company

RemeGen Appoints He Ruyi as Chief Strategy Officer, Transitioning from CMO Role

Fineline Cube Aug 16, 2024

RemeGen (HKG: 9995), a China-based pharmaceutical company, has appointed He Ruyi as its new Chief...

Company Drug

Kelun Pharmaceutical’s Sacituzumab Tirumotecan Receives Priority Review for NSCLC Treatment

Fineline Cube Aug 16, 2024

Sichuan Kelun Pharmaceutical Co., Ltd. (SHE: 002422) has announced that its drug sacituzumab tirumotecan (SKB264/MK-2870)...

Company Deals

Huadong Medicine Secures Licensing Deal with IMBiologics for Autoimmune Drug Candidates

Fineline Cube Aug 16, 2024

Huadong Medicine Co., Ltd. (SHE: 000963), a Chinese pharmaceutical company, has entered into a licensing...

Company Drug

Lykos Therapeutics Faces Setback as FDA Rejects Midomafetamine for PTSD Treatment

Fineline Cube Aug 16, 2024

Lykos Therapeutics, a U.S.-based biotech firm, has expressed concern over the impact of the FDA’s...

Company Drug

Chugai Seeks Approval for Elevidys Gene Therapy in Japan, Targeting Duchenne Muscular Dystrophy

Fineline Cube Aug 16, 2024

Chugai Pharmaceutical Co., Ltd. (TYO: 4519), a subsidiary of Roche, has submitted a product approval...

Company Drug

Staidson Launches Phase Ia Trial for STSP-0902 Injection in Oligoasthenozoospermia

Fineline Cube Aug 16, 2024

Staidson (Beijing) Pharmaceutical Co., Ltd. (SHE: 300204) has announced that it has received approval from...

Company Drug

Jiangsu Hengrui Secures NMPA Approval for Clinical Trials of SHR-2106 in Primary Sjögren’s Syndrome

Fineline Cube Aug 16, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received clinical trial...

Company Medical Device

Lepu Scientech Secures NMPA Approval for MemoSORB Biodegradable Atrial Septal Defect Occluder

Fineline Cube Aug 16, 2024

Lepu Scientech Medical Technology (Shanghai) Co., Ltd. (HKG: 2291) has announced that it has received...

Company Medical Device

Sino Medical Secures Moroccan Approvals for NC Rockstar Catheter and HT Supreme Stent System

Fineline Cube Aug 16, 2024

Sino Medical Sciences Technology Inc. (SHA: 688108), a prominent player in China’s medical device sector,...

Company Drug

Vimgreen Pharma Launches Phase II Trial for A2AR Antagonist VG081821AC in Parkinson’s Disease

Fineline Cube Aug 16, 2024

Zhejiang-based Vimgreen Pharma has announced the launch of a Phase II clinical trial for its...

Company Drug

Gilead Secures FDA Accelerated Approval for Livdelzi in Liver Disease Treatment

Fineline Cube Aug 15, 2024

Gilead Sciences Inc. (NASDAQ: GILD) has received accelerated approval from the U.S. FDA for its...

Company Drug

Astellas Pharma Secures UK Approval for First-in-Class Gastric Cancer Therapy Vyloy

Fineline Cube Aug 15, 2024

Astellas Pharma (TYO: 4503), a leading Japanese pharmaceutical company, has secured market approval in the...

Company

GSK’s Ma Zheng to Depart as Head of Communication and Government Affairs in China

Fineline Cube Aug 15, 2024

Ma Zheng, the head of communication and government affairs for GSK plc (NYSE: GSK) in...

Company Deals Medical Device

Shanghai Sanyou Medical to Acquire Full Control of SMTP Technology for RMB 415.7 Million

Fineline Cube Aug 15, 2024

Shanghai Sanyou Medical Co., Ltd. (SHA: 688085), based in China, is set to acquire the...

Company Deals Drug

Shandong Buchang Pharmaceuticals Partners with Lancet for BC001 Licensing in Eurasia

Fineline Cube Aug 15, 2024

Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858), based in China, has announced plans to enter...

Company Drug

Biogen and Eisai Secure UAE Approval for Alzheimer’s Therapy Leqembi

Fineline Cube Aug 15, 2024

Biogen Inc. (NASDAQ: BIIB), based in the U.S., and Japan’s Eisai Co., Ltd. have announced...

Policy / Regulatory

Shaanxi Leads New Provincial Alliance for Volume-Based Procurement of Medical Products

Fineline Cube Aug 15, 2024

The Shaanxi Public Resources Trading Center has announced the formation of a provincial alliance for...

Posts pagination

1 … 260 261 262 … 613

Recent updates

  • Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services
  • Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials
  • PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline
  • J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth
  • AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services

Company Drug

Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials

Company Deals

PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline

Company

J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.